{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"GNPX","limit":50},"count":50,"signals":[{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":57,"context":"y or manufacture our products on a timely, consistent basis in a manner sufficient and appropriate as is commensurate to meet our clinical trial timing, courses of treatment, and other requisite fulfillment considerations necessary to adequately advance our development programs; |  | |  |  |  Our ability to conduct and complete our clinical trials in accordance with projected timelines; |  | **** |","filed_date":"2026-03-30","accession":"0001437749-26-010346","full_text":"https://origin.rootz.global/static/filing/0001437749-26-010346.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":48,"context":"y to maintain and protect intellectual property rights; |  | **** |  |  |  The effects and impacts of public health crises such as epidemics or outbreaks, which could significantly disrupt and have a material adverse effect upon our business, our clinical trials andour research programs; as well as onhealthcare systems or the global economy as a whole; |  | **** |  |  |  The success of our clinical trials through all ph","filed_date":"2026-03-30","accession":"0001437749-26-010346","full_text":"https://origin.rootz.global/static/filing/0001437749-26-010346.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"However, as previously announced in *August 2024,*based on resource prioritization and to focus on the patients for whom REQORSA is most likely to show a benefit, the Company decided to limit its enrollment efforts moving forward to patients who received only prior Tagrisso treatment and cease enrollment of the *second* cohort (patients who received prior Tagrisso treatment and chemotherapy). However","filed_date":"2025-11-14","accession":"0001437749-25-035191","full_text":"https://origin.rootz.global/static/filing/0001437749-25-035191.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":32,"context":"Date shall have the meaning ascribed to such term in Section 4.1(c). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Money Laundering Laws shall have the meaning ascribed","filed_date":"2025-10-29","accession":"0001437749-25-032081","full_text":"https://origin.rootz.global/static/filing/0001437749-25-032081.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":32,"context":"Date shall have the meaning ascribed to such term in Section 4.1(c). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Money Laundering Laws shall have the meaning ascribed","filed_date":"2025-10-24","accession":"0001437749-25-031678","full_text":"https://origin.rootz.global/static/filing/0001437749-25-031678.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"However, as previously announced in *August 2024,*based on resource prioritization and to focus on the patients for whom REQORSA is most likely to show a benefit, the Company decided to limit its enrollment efforts moving forward to patients who received only prior Tagrisso treatment and cease enrollment of the *second* cohort (patients who received prior Tagrisso treatment and chemotherapy). However","filed_date":"2025-08-14","accession":"0001437749-25-026965","full_text":"https://origin.rootz.global/static/filing/0001437749-25-026965.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":31,"context":"ull proportionate adjustment thereto made pursuant to Section 2(a) hereof for or in respect of such reorganization, recapitalization, non-cash dividend, stock split or other similar transaction. (cc) Material Adverse Effect means any material adverse effect on (i)the enforceability of any Transaction Document, (ii)the results of operations, assets, business or financial condition of the Company and its Subsidiaries, tak","filed_date":"2025-07-16","accession":"0001437749-25-022834","full_text":"https://origin.rootz.global/static/filing/0001437749-25-022834.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":50,"context":"independent registered public accounting firm for our fiscal year ending December 31, 2025; (iii) we will ask stockholders to approve, on an advisory basis, the executive compensation of the Companys named executive officers as described in the proxy statement; (iv) we will ask stockholders to approve an amendment and restatement of our 2018 Equity Incentive Plan; (v) we will ask stockholders to approve, for purposes of","filed_date":"2025-07-16","accession":"0001437749-25-022834","full_text":"https://origin.rootz.global/static/filing/0001437749-25-022834.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"ull proportionate adjustment thereto made pursuant to Section 2(a) hereof for or in respect of such reorganization, recapitalization, non-cash dividend, stock split or other similar transaction. (cc) Material Adverse Effect means any material adverse effect on (i) the enforceability of any Transaction Document, (ii) the results of operations, assets, business or financial condition of the Company and its Subsidiaries, t","filed_date":"2025-06-11","accession":"0001437749-25-020102","full_text":"https://origin.rootz.global/static/filing/0001437749-25-020102.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":22,"context":"currently analyzing biomarkers that would indicate lack of response in lung cancer that could enrich the Companys population of responders in its clinical trials and enhance patient screening and enrollment in order to increase the likelihood of potential success of the Acclaim studies for the Company. Acclaim *1:* The Company currently is enrolling and treating patients in the Phase *2a* expansion p","filed_date":"2025-05-12","accession":"0001437749-25-016133","full_text":"https://origin.rootz.global/static/filing/0001437749-25-016133.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":63,"context":"y or manufacture our products on a timely, consistent basis in a manner sufficient and appropriate as is commensurate to meet our clinical trial timing, courses of treatment, and other requisite fulfillment considerations necessary to adequately advance our development programs; |  | |  |  |  Our ability to conduct and complete our clinical trials in accordance with projected timelines; |  | **** |","filed_date":"2025-04-01","accession":"0001437749-25-010311","full_text":"https://origin.rootz.global/static/filing/0001437749-25-010311.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":50,"context":"and the narrowness of the exceptions and safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge could have a material adverse effect on our business, financial condition, and results of operations. If our operations are found to be in violation of any of these or any other health regulatory laws that may apply to us, we may be sub","filed_date":"2025-04-01","accession":"0001437749-25-010311","full_text":"https://origin.rootz.global/static/filing/0001437749-25-010311.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":29,"context":"of the total number of directors, and each class has a three-year term. Vacancies on the Board of Directors may be filled only by persons elected by a majority of the remaining directors. A director elected by the Board of Directors to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the directors successor is","filed_date":"2025-04-01","accession":"0001437749-25-010311","full_text":"https://origin.rootz.global/static/filing/0001437749-25-010311.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":23,"context":"currently analyzing biomarkers that would indicate lack of response in lung cancer that could enrich the Companys population of responders in its clinical trials and enhance patient screening and enrollment in order to increase the likelihood of potential success of the Acclaim studies for the Company. *Acclaim-3*: The Company is currently enrolling and treating patients in the Phase *1* dose escalat","filed_date":"2024-11-13","accession":"0001437749-24-034697","full_text":"https://origin.rootz.global/static/filing/0001437749-24-034697.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"currently analyzing biomarkers that would indicate lack of response in lung cancer that could enrich the Companys population of responders in its clinical trials and enhance patient screening and enrollment in order to increase the likelihood of potential success of the Acclaim studies for the Company. *Acclaim-3*: The Company is currently enrolling and treating patients in the Phase *1* dose escalat","filed_date":"2024-08-09","accession":"0001437749-24-025893","full_text":"https://origin.rootz.global/static/filing/0001437749-24-025893.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":38,"context":"independent registered public accounting firm for our fiscal year ending December 31, 2024; (iii) we will ask stockholders to approve, on an advisory basis, the executive compensation of the Companys named executive officers as described in the proxy statement; and (iv) we will ask stockholders to vote, on an advisory basis, on how often we will conduct an advisory vote on executive compensation. We may also ask stockho","filed_date":"2024-04-29","accession":"0001437749-24-013693","full_text":"https://origin.rootz.global/static/filing/0001437749-24-013693.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":41,"context":"y or manufacture our products on a timely, consistent basis in a manner sufficient and appropriate as is commensurate to meet our clinical trial timing, courses of treatment, and other requisite fulfillment considerations necessary to adequately advance our development programs; |  | |  |  |  Our ability to conduct and complete our clinical trials in accordance with projected timelines; |  | **** |","filed_date":"2024-04-01","accession":"0001437749-24-010426","full_text":"https://origin.rootz.global/static/filing/0001437749-24-010426.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":48,"context":"and the narrowness of the exceptions and safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge could have a material adverse effect on our business, financial condition, and results of operations. If our operations are found to be in violation of any of these or any other health regulatory laws that may apply to us, we may be sub","filed_date":"2024-04-01","accession":"0001437749-24-010426","full_text":"https://origin.rootz.global/static/filing/0001437749-24-010426.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":32,"context":"ata shall have the meaning ascribed to such term in Section 3.1(mm). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Money Laundering Laws shall have the meaning ascribed","filed_date":"2024-03-20","accession":"0001437749-24-008592","full_text":"https://origin.rootz.global/static/filing/0001437749-24-008592.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":29,"context":"to such term in Section 3(v). Issuer Free Writing Prospectus shall mean an issuer free writing prospectus, as defined in Rule 433. Losses shall have the meaning ascribed to such term in Section 7(d). Material Adverse Effect shall have the meaning ascribed to such term in Section 3(b). Material Permits shall have the meaning ascribed to such term in Section 3(t). Net Proceeds shall have the meaning ascribed to such term","filed_date":"2023-12-13","accession":"0001437749-23-034341","full_text":"https://origin.rootz.global/static/filing/0001437749-23-034341.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"reatment* combination of REQORSA and Tagrisso in NSCLC patients who have progressed after Tagrisso treatment.&#xa0; We are working towards opening the Phase *2* expansion portion of the trial for enrollment as soon as reasonably practicable and expect this will occur between *December 2023*and the end of the *first* quarter of *2024,* subject to the availability of a new batch of REQORSA. &#xa0; *Acc","filed_date":"2023-11-14","accession":"0001437749-23-031830","full_text":"https://origin.rootz.global/static/filing/0001437749-23-031830.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":31,"context":"ata shall have the meaning ascribed to such term in Section 3.1(mm). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Money Laundering Laws shall have the meaning ascribed","filed_date":"2023-07-19","accession":"0001437749-23-020227","full_text":"https://origin.rootz.global/static/filing/0001437749-23-020227.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":20,"context":"of the total number of directors, and each class has a three-year term. Vacancies on the Board of Directors may be filled only by persons elected by a majority of the remaining directors. A director elected by the Board of Directors to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the directors successor is","filed_date":"2023-04-28","accession":"0001437749-23-011497","full_text":"https://origin.rootz.global/static/filing/0001437749-23-011497.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"y or cause to be paid the Principal of, and interest on, each of the Securities of such series at the place or places, at the respective times and in the manner provided in such Securities. Each installment of interest on the Securities of any series may be paid by mailing checks for such interest payable to or upon the written order of the Holders of Securities entitled thereto as they shall appear","filed_date":"2023-04-21","accession":"0001437749-23-010816","full_text":"https://origin.rootz.global/static/filing/0001437749-23-010816.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":42,"context":"oved escalating the dose from 0.09 mg/kg in the second cohort to 0.12 mg/kg in the third and final cohort. We are thus enrolling and treating patients at the 0.12 mg/kg dose&#xa0;level. We expect enrollment in the dose escalation portion of the study to be completed in the next several days following the filing of this Annual Report. After completion of enrollment and cycle one of treatment for the r","filed_date":"2023-03-31","accession":"0001437749-23-008847","full_text":"https://origin.rootz.global/static/filing/0001437749-23-008847.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"and the narrowness of the exceptions and safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge could have a material adverse effect on our business, financial condition, and results of operations. If our operations are found to be in violation of any of these or any other health regulatory laws that may apply to us, we may be sub","filed_date":"2023-03-31","accession":"0001437749-23-008847","full_text":"https://origin.rootz.global/static/filing/0001437749-23-008847.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"triction. Lock-Up Agreement means the Lock-Up Agreement, dated as of the date hereof, by and among the Company and the directors and officers of the Company, in the form of Exhibit C attached hereto. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(m). Per Share Purchase Price equals $1.05, subject to adju","filed_date":"2023-02-27","accession":"0001437749-23-004771","full_text":"https://origin.rootz.global/static/filing/0001437749-23-004771.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":38,"context":"place where the nature of its properties or the conduct of its business requires such registration or qualification, except where the failure to so register or qualify has not had or will not have a material adverse effect on the condition (financial or other), business, properties, net worth or results of operations or prospects of the Company and its Subsidiaries (a Material Adverse Effect). (5) No Prohibition on Div","filed_date":"2022-11-18","accession":"0001437749-22-027745","full_text":"https://origin.rootz.global/static/filing/0001437749-22-027745.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":21,"context":"of the total number of directors, and each class has a three-year term. Vacancies on the Board of Directors may be filled only by persons elected by a majority of the remaining directors. A director elected by the Board of Directors to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the directors successor is","filed_date":"2022-04-28","accession":"0001437749-22-010097","full_text":"https://origin.rootz.global/static/filing/0001437749-22-010097.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"atients with Stage IV (metastatic) or recurrent NSCLC that is not potentially curable by radiotherapy or surgery.&#xa0; Patients were enrolled whether or not they had an activating EGFR mutation. Enrollment in the Phase 1 portion of the Phase 1/2 Combination Tarceva Trial commenced in 2014 at MD Anderson with Dr. Charles Lu as the Principal Investigator. &#xa0; In the Phase 1&#xa0;portion of the Phas","filed_date":"2022-03-30","accession":"0001437749-22-007680","full_text":"https://origin.rootz.global/static/filing/0001437749-22-007680.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":26,"context":"and the narrowness of the exceptions and safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge could have a material adverse effect on our business, financial condition, and results of operations. If our operations are found to be in violation of any of these or any other health regulatory laws that may apply to us, we may be sub","filed_date":"2022-03-30","accession":"0001437749-22-007680","full_text":"https://origin.rootz.global/static/filing/0001437749-22-007680.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":29,"context":"he virtual meeting, and information about Genprex, Inc. that you should consider when you vote your shares are described in the accompanying proxy statement. At the annual meeting, one person will be elected to our Board of Directors. In addition, we will ask stockholders to ratify the appointment of Daszkal Bolton LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2021. The Board of","filed_date":"2021-04-30","accession":"0001437749-21-010447","full_text":"https://origin.rootz.global/static/filing/0001437749-21-010447.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"rsely affect our ability to conduct our business or obtain regulatory approvals for our current and future product candidates. |  | |  |  |  Conducting successful clinical studies may require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. |  | |  |  |  The accelerated approval pathway for our product candidates may not lead to a faster dev","filed_date":"2021-03-26","accession":"0001437749-21-007317","full_text":"https://origin.rootz.global/static/filing/0001437749-21-007317.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"ct candidates, if approved, which could make it difficult for us to sell REQORSA, GPX-002 and our future product candidates profitably. |  | |  |  |  Healthcare legislative reform measures may have a material adverse effect on our business and results of operations. |  | |  |  |  We are subject to a variety of risks associated with international operations which could materially adversely affect our business. |  | **Ris","filed_date":"2021-03-26","accession":"0001437749-21-007317","full_text":"https://origin.rootz.global/static/filing/0001437749-21-007317.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":29,"context":"scribed to such term in Section 3.1(qq). Lien means a lien, charge, mortgage, pledge, security interest, claim, right of first refusal, pre-emptive right, or other encumbrance of any kind whatsoever. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning assigned to such term in Section 3.1(r). Money Laundering Laws shall have the meaning assigned","filed_date":"2021-02-09","accession":"0001437749-21-002350","full_text":"https://origin.rootz.global/static/filing/0001437749-21-002350.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":29,"context":"scribed to such term in Section 3.1(qq). Lien means a lien, charge, mortgage, pledge, security interest, claim, right of first refusal, pre-emptive right, or other encumbrance of any kind whatsoever. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning assigned to such term in Section 3.1(r). Money Laundering Laws shall have the meaning assigned","filed_date":"2020-12-23","accession":"0001437749-20-025883","full_text":"https://origin.rootz.global/static/filing/0001437749-20-025883.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":33,"context":"e virtual meeting, and information about Genprex, Inc. that you should consider when you vote your shares are described in the accompanying proxy statement. At the annual meeting, two persons will be elected to our Board of Directors. In addition, we will ask stockholders to ratify the appointment of Daszkal Bolton LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020. The Board of","filed_date":"2020-04-29","accession":"0001437749-20-008761","full_text":"https://origin.rootz.global/static/filing/0001437749-20-008761.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"ECIST, as Complete Response (CR) + Partial Response (PR); disease control rate is defined under the RECIST criteria as Complete Response (CR) + Partial Response (PR) + Stable Disease (SD)>8weeks. Enrollment criteria for the second phase of the Phase I/II clinical trial were identical to those in the first phase. The Phase II portion of the trial began in June 2015. Of the 39 patients allowed in the p","filed_date":"2020-03-30","accession":"0001437749-20-006522","full_text":"https://origin.rootz.global/static/filing/0001437749-20-006522.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":20,"context":"sions or withdrawals of approvals, operating restrictions, interruptions in supply and criminal prosecutions, any of which could significantly and adversely affect supplies of our Oncoprex and have a material adverse impact on our business, financial condition and results of operations. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved mar","filed_date":"2020-03-30","accession":"0001437749-20-006522","full_text":"https://origin.rootz.global/static/filing/0001437749-20-006522.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":18,"context":"arly situated employees of the Company); or (iv) the relocation of the Employee to a facility or a location more than fifty (50) miles from Employees then current location.  **8****.********Effect of Separation from Service**. For purposes of this Agreement, no payment will be made to Employee upon termination of Employees employment unless such termination constitutes a separation from service within the meanin","filed_date":"2020-03-23","accession":"0001437749-20-005893","full_text":"https://origin.rootz.global/static/filing/0001437749-20-005893.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"ph Gunnar & Co. LLC, co-placement agent. Lien means a lien, charge, mortgage, pledge, security interest, claim, right of first refusal, pre-emptive right, or other encumbrance of any kind whatsoever. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning assigned to such term in Section 3.1(r). 3 Money Laundering Laws shall have the meaning assigne","filed_date":"2020-02-20","accession":"0001437749-20-003170","full_text":"https://origin.rootz.global/static/filing/0001437749-20-003170.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"ph Gunnar & Co. LLC, co-placement agent. Lien means a lien, charge, mortgage, pledge, security interest, claim, right of first refusal, pre-emptive right, or other encumbrance of any kind whatsoever. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning assigned to such term in Section 3.1(r). Money Laundering Laws shall have the meaning assigned","filed_date":"2020-01-24","accession":"0001437749-20-001173","full_text":"https://origin.rootz.global/static/filing/0001437749-20-001173.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":16,"context":"perty Rights shall have the meaning ascribed to such term in Section 3.1(o). Liens means a lien, charge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(m). Per Share Purchase Price equals $0.24, subject to adju","filed_date":"2020-01-17","accession":"0001437749-20-000815","full_text":"https://origin.rootz.global/static/filing/0001437749-20-000815.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"Date shall have the meaning ascribed to such term in Section 4.1(c). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Per Share Purchase Price equals $0.40, subject to adju","filed_date":"2019-11-22","accession":"0001437749-19-023451","full_text":"https://origin.rootz.global/static/filing/0001437749-19-023451.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":22,"context":"our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed, the number of patients enrolled and the rate of patient enrollment may vary from our estimates and could result in us reporting amounts that are higher or lower than the actual amounts for any particular period. Our accrued expenses are dependent, in part, upon t","filed_date":"2019-11-14","accession":"0001437749-19-022847","full_text":"https://origin.rootz.global/static/filing/0001437749-19-022847.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"nt from third-party payors for our current and potential product candidates and may be affected by existing and future health care reform measures. **Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.** Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcar","filed_date":"2019-11-14","accession":"0001437749-19-022847","full_text":"https://origin.rootz.global/static/filing/0001437749-19-022847.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":22,"context":"our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed, the number of patients enrolled and the rate of patient enrollment may vary from our estimates and could result in us reporting amounts that are higher or lower than the actual amounts for any particular period. Our accrued expenses are dependent, in part, upon t","filed_date":"2019-10-16","accession":"0001437749-19-020138","full_text":"https://origin.rootz.global/static/filing/0001437749-19-020138.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"nt from third-party payors for our current and potential product candidates and may be affected by existing and future health care reform measures. **Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.** Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcar","filed_date":"2019-10-16","accession":"0001437749-19-020138","full_text":"https://origin.rootz.global/static/filing/0001437749-19-020138.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":36,"context":"ECIST, as Complete Response (CR) + Partial Response (PR); disease control rate is defined under the RECIST criteria as Complete Response (CR) + Partial Response (PR) + Stable Disease (SD)>8weeks. Enrollment criteria for the second phase of the Phase I/II clinical trial are identical to those in the first phase. The Phase II portion of the trial began in June 2015 and is ongoing at MD Anderson. Of the","filed_date":"2019-10-16","accession":"0001437749-19-020136","full_text":"https://origin.rootz.global/static/filing/0001437749-19-020136.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GNPX","company":"Genprex, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":19,"context":"on of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. Within the FDA, the Center for Biologics Evaluation and Research, or CBER, regulates gene therapy products. CBER works closely with the National Institutes of Health, or NIH, and its Recombina","filed_date":"2019-10-16","accession":"0001437749-19-020136","full_text":"https://origin.rootz.global/static/filing/0001437749-19-020136.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"7e6b016dd61b66ba7a1e029c5075ce2b4259df055f6c4cef6aeb3732e054d244","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"10ad57e3eab528d6ca7b10cae4677854edf6283e6232ea3761037fc416e6cf7d","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":91,"hourly_limit":500,"remaining":409,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}